BETA
Single-use robotic technology for remotely controlled endovascular catheter and guidewire manipulation.
Microbot Medical develops LIBERTY, a single-use robotic system designed to support endovascular procedures through remote manipulation of catheters and guidewires. The platform is intended to reduce the need for operators to stand beside the patient during device manipulation.
FDA cleared the LIBERTY Endovascular Robotic System in September 2025. The company announced full U.S. market release in April 2026. The clearance belongs to the specifically identified system and does not establish autonomous operation or authorization across all vascular anatomies.
Harel Gadot leads the company as CEO, president and chairman. Microbot has U.S. commercial operations and Israeli development capabilities; scaling the platform involves account development, physician training and integration with existing endovascular workflows.
LIBERTY has FDA 510(k) clearance K243789 for the specified peripheral endovascular robotic system. Company materials document commercialization; additional procedures or future applications require their own supporting regulatory evidence. [10][13][2][12][1]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [6][4]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Remotely operated manipulation of compatible endovascular devices. [10][9]
FDA-clearedCommercially offered; exact model and country availability should be confirmed with the manufacturer.
Commercial launch follows device-specific 510(k) clearance; further applications require separate evidence. [10][13]
Company announced full U.S. release of LIBERTY. [13]
Accessed 10/29/2026